Cleerly enables comprehensive phenotyping of coronary artery disease, as determined from advanced non-invasive CT imaging. Cleerly's digital care pathway leverages non-invasive coronary computed tomography (CT) angiography to perform comprehensive coronary artery phenotyping through AI-enabled and FDA-cleared solutions. This technology is based on millions of annotated lab images used to build more than two dozen proprietary algorithms capable of quantifying and characterizing the presence, extent, severity and type of coronary artery disease and other cardiovascular disorders.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/21/21 | $43,000,000 | Series B |
American College of Cardiology DigiTx Partners LRVHealth New Leaf Venture Partners Vensana Capital  | undisclosed |
